

Docket No.: B2368C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hindley et al.

9 August 1996

Serial No: 08/458,033

Group Art Unit: 1201

Filed: December 19, 1994

Examiner: R. Gerstl

For: NOVEL COMPOUNDS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 09 1996 JU

MATRIX CUSTOMER
SERVICE CENTER

SUPPLEMENTAL AMENDMENT AND REQUEST THAT AN
INTERFERENCE BE DECLARED UNDER RULE 607

Sir:

Further to the response submitted June 21, 1996, please amend this application as follows:

AMENDMENT

IN THE CLAIMS:

Please add claims 14 and 15 as follows:

-- 14. A method of treating impaired glucose tolerance comprising administering to a host suffering therefrom a therapeutically effective amount of a compound selected from the group consisting of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione and 5-(4-(2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione.

15. The method of claim 14, wherein the compound is 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione.--